Company profile: Xspray Pharma
1.1 - Company Overview
Company description
- Provider of improved and generic versions of marketed protein kinase inhibitors, using patented Hynap Technology to create amorphous formulations for faster post-patent entry. Portfolio includes Dasynoc (improved dasatinib for CML/ALL with lower dose, reduced absorption variability, and gastric acid suppressant compatibility), XS004 (dasatinib), and XS025 (cabozantinib for renal cell carcinoma and other cancers).
Products and services
- Hynap Technology: Patented, amorphous-formulation platform that engineers versions of marketed protein kinase inhibitors to improve formulations and enable faster market entry following patent expiration
- Dasynoc: Formulation-optimized dasatinib for CML and ALL that reduces dosage requirements, decreases absorption variability, and remains effective alongside gastric acid suppressants
- XS025: US-market-targeted cabozantinib product candidate engineered for renal cell carcinoma and other cancers, based on cabozantinib and explicitly aimed at the US market.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Xspray Pharma
Ikena Oncology
HQ: United States
Website
- Description: Provider of novel biomarker-driven targeted cancer therapies, advancing a pipeline focused on the Hippo and RAS signaling pathways to address cancer growth, spread, and resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikena Oncology company profile →
Peptomyc
HQ: Spain
Website
- Description: Provider of next-generation cell-penetrating peptides targeting the Myc oncoprotein for cancer treatment. Built on Dr. Soucek’s Omomyc research, the company’s lead candidate, OMO-103, is an Omomyc-derived therapeutic peptide designed to inhibit the deregulated Myc oncoprotein in many cancers to halt tumor growth and progression. Founded in December 2014.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Peptomyc company profile →
Orionis Biosciences
HQ: United States
Website
- Description: Provider of biotechnology platforms for healthcare innovation, including the A-Kine platform for engineering cytokines with targeted cell selectivity and controlled activity for cancer immunotherapy, and the Allo-Glue platform for discovering and designing small molecule molecular glues to modulate or degrade disease targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orionis Biosciences company profile →
YM BioSciences
HQ: Canada
Website
- Description: Provider of life sciences product development services focused on identifying and advancing a diverse portfolio of cancer-related products at various stages of development, leveraging regulatory and clinical trial expertise and a diversified business model to reduce risk while advancing clinical products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full YM BioSciences company profile →
TME Pharma
HQ: Germany
Website
- Description: Provider of biostable aptamer therapeutics based on mirror image nucleic acids, including NOX-A12 to enhance anti-cancer treatments in glioblastoma and pancreatic cancer and NOX-E36 to improve tumor immune response. Operates GLORIA, OPERA & OPTIMUS trials, and pursues collaborations, including a strategic alliance with Pfizer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TME Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Xspray Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Xspray Pharma
2.2 - Growth funds investing in similar companies to Xspray Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Xspray Pharma
4.2 - Public trading comparable groups for Xspray Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →